UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
View all comments(0)
Brokerage UBS raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $129 from $88; setting it in line with Sanofi's buyout price for the co
Maintains "neutral" rating
French drugmaker Sanofi SASY.PA said on Monday it has agreed to buy BPMC for up to $9.5 billion to boost its position in rare immunology diseases
UBS sees limited or no overlap in both companies' portfolios
Sanofi gains Ayvakit to treat a type of rare immunology disease called advanced and indolent systemic mastocytosis with $478.9 million revenue in 2024 - UBS
Including session's moves, stock up 46.9% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.